Overview

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes, when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety of this treatment will also be studied
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Astra Zeneca, Bristol-Myers Squibb
Treatments:
Dapagliflozin
Metformin